Loading clinical trials...

LUNG-ROLL: Treatment Patterns and Cost of Illness of Lung Cancer in Canada | Clinical Trials | Clareo Health

RECRUITING

LUNG-ROLL: Treatment Patterns and Cost of Illness of Lung Cancer in Canada

NCT07143110•AstraZeneca

Summary

LUNG-ROLL is a retrospective cohort study that will describe the contemporary treatment patterns, prevalence and incidence, patient demographic and clinical characteristics, clinical outcomes, and healthcare resource use/costs for patients with lung cancer in Canada (specifically, Alberta and Ontario) using administrative data.

Eligibility

Age

18 - 130 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Patients with lung cancer between January 1, 2018 and end of the Selection Period.
•Patient is 18 years of age or older on diagnosis date.
•Patient has at least 12 months of health insurance coverage prior to the diagnosis date.

Exclusion Criteria

•Diagnosed with any other cancer in the 5-year period prior to January 1, 2018.
•Diagnosed with any other cancer concurrently (i.e., on the same date) as lung cancer diagnosis.
•Invalid or incomplete records for key variables (e.g., missing year of diagnosis, missing cancer type).
•Non-Ontario or non-Alberta resident on diagnosis date.

Locations (2)

Research Site

Calgary, Alberta, Canada

Research Site

Toronto, Ontario, Canada

Key Dates

Start Date

August 20, 2025

Primary Completion Date

September 30, 2027

Completion Date

September 30, 2027

Last Updated

March 2, 2026

Enrollment

60,000

ESTIMATED participants

Conditions

Lung Neoplasms

Contacts

AstraZeneca Clinical Study Information Center

CONTACT

1-877-240-9479 information.center@astrazeneca.com

Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma

NCT06885697

MesotheliomaNeoplasms+6 more

View study

RECRUITINGNA

Lung B.A.S.E.S. 4 Life Mobile Low-dose Computed Tomography (LDCT) Screening: Ages 40-54

NCT04577599

Lung NeoplasmsLung Cancer

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 2, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

LUNG-ROLL: Treatment Patterns and Cost of Illness of Lung Cancer in Canada

Inclusion Criteria

Exclusion Criteria

Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma

Lung B.A.S.E.S. 4 Life Mobile Low-dose Computed Tomography (LDCT) Screening: Ages 40-54

Preventing Dato-DXd Associated Stomatitis With Dexamethasone Mouthwash, TROPION-DM

Diagnosis of Multiple Cancer and Monitoring of Minimal Residual Tumors After Treatment Using Blood and High-Sensitivity Genetic Analysis Techniques

Mediastinal Lymph Node Dissection Versus Spared Mediastinal Lymph Node Dissection in Stage I GGN NSCLC

Establishment of a Tumor Bank for Tissue Samples